The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Big pharma interest remains, but the mood is fast turning gloomy.
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
The recently unveiled conjugate DS3610a is to start phase 1.
So who else could be interested in the oestrogen degrader?
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.